Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 13/20 | 0.57 |
| ▸ | IKBKB | O14920 | 3/20 | 0.48 |
| ▸ | JAK2 | O60674 | 2/20 | 0.48 |
| ▸ | JAK3 | P52333 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | EIF2AK2 | P19525 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2344574 | 0.89 | CHEK1 (0.59) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2282391 | 0.89 | CHEK1 (0.59) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL1148018 | 0.88 | CHEK1 (0.56) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2346009 | 0.88 | CHEK1 (0.56) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2283636 | 0.87 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2282382 | 0.86 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2278138 | 0.86 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2285911 | 0.86 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2282387 | 0.86 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 | |
| SCHEMBL2285905 | 0.86 | CHEK1 (0.54) | CHEK1IKBKBJAK2JAK3MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8003695-B2 | IKK-beta serine-threonine protein kinase inhibitors | CHROMA THERAPEUTICS LTD. (GB) | 2011-08-23 | — | — | US | disclosed |